Nantahala Capital Management LLC Takes Position in TELA Bio, Inc. $TELA

Nantahala Capital Management LLC acquired a new stake in TELA Bio, Inc. (NASDAQ:TELA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,894,114 shares of the company’s stock, valued at approximately $4,420,586. Nantahala Capital Management LLC owned about 13.13% of TELA Bio as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of TELA. Essex Woodlands Management Inc. lifted its position in shares of TELA Bio by 87.7% in the 4th quarter. Essex Woodlands Management Inc. now owns 7,714,709 shares of the company’s stock worth $9,103,000 after buying an additional 3,604,000 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in shares of TELA Bio in the 2nd quarter valued at about $1,996,820. Perkins Capital Management Inc. grew its position in shares of TELA Bio by 67.6% during the 4th quarter. Perkins Capital Management Inc. now owns 1,397,418 shares of the company’s stock valued at $1,649,000 after buying an additional 563,490 shares during the last quarter. BlackRock Inc. bought a new stake in shares of TELA Bio during the 2nd quarter valued at about $281,000. Finally, UP Strategic Wealth Investment Advisors LLC bought a new stake in shares of TELA Bio during the 2nd quarter valued at about $91,000. Institutional investors and hedge funds own 94.35% of the company’s stock.

TELA Bio Stock Performance

Shares of NASDAQ TELA opened at $0.70 on Friday. The stock has a fifty day moving average price of $0.74 and a two-hundred day moving average price of $0.78. The company has a debt-to-equity ratio of 8.82, a quick ratio of 2.38 and a current ratio of 2.99. The firm has a market cap of $31.43 million, a P/E ratio of -0.91 and a beta of 1.34. TELA Bio, Inc. has a 1 year low of $0.50 and a 1 year high of $1.87.

TELA Bio (NASDAQ:TELA) last released its earnings results on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 51.53%.The firm had revenue of $19.29 million for the quarter, compared to analyst estimates of $20.01 million. Research analysts forecast that TELA Bio, Inc. will post -0.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.20.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial?stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.